Kim et al. additionally proved that tumour growth could be inhibited by treatment with FGFR2-inhibitor (TKI258) using NOD/SCID mouse models xenografted with breast cancer tumours overexpressing FGFR2. Here, FGFR2 is linked to breast carcinoma.